Cronos Group
CRON
3.04
-0.04
-1.30%
Cronos Group
US · CRON
#3133 by market cap
Listed 1970
3.04
-0.04
-1.30%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Citron Founder, a Short-Selling Giant, on Trial: CEO of Cronos Group (CRON.US) Cross-Examined, Unveiling Details of Alleged 'Short-and-Smear' SchemeZhitong Finance · 2026/5/13
-
Rating change
Analysts Offer Insights on Healthcare Companies: Community Health (CYH) and Cronos Group (CRON)TipRanks · 2026/9/28
-
Rating change
Cronos Group (CRON) Gets a Hold From BernsteinTipRanks · 2026/1/14
-
Rating change
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Cronos Group (CRON)TipRanks · 2026/8/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Cronos Group (CRON)TipRanks · 2024/5/15
-
Rating change
Bernstein Initiates Cronos Group(CRON.US) With Hold RatingMarket Newswire · 2026/5/12
-
Rating change
Jefferies Remains a Hold on Cronos Group (CRON)TipRanks · 2024/5/18
-
Rating change
CIBC: Maintaining the Cronos Group (CRON.US) rating, adjusted from Outperformer to Outperformer rating, and adjusted the target price from $3.00 to $3.50.Zhitong Finance · 2024/5/15
-
Rating change
Roth MKM Initiates Cronos Group(CRON.US) With Buy RatingMarket Newswire · 2025/7/19
-
Cronos Completes Acquisition Of CanAdelaar, Europe's Largest Adult-Use Cannabis Company CRON.TDow Jones · 2026/10/15
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)TipRanks · 2024/8/9
-
Rating change
BofA Securities Maintains Cronos Group(CRON.US) With Sell Rating, Cuts Target Price to $1.65Market Newswire · 2025/4/8
-
Rating change
B of A Securities: Maintaining the Cronos Group (CRON.US) rating, adjusted from below the market to below the market rating, and adjusted the target price from $2.00 to $2.50.Zhitong Finance · 2024/4/8
-
Earnings Flash (CRON) Cronos Group Inc. Reports Q1 Revenue $45.2M, Vs. FactSet Est of $42.2MMT Newswires · 2026/5/11
-
Rating change
TD Cowen Initiates Cronos Group(CRON.US) With Buy Rating, Announces Target Price $3.28Market Newswire · 2026/2/24
-
Rating change
BofA Securities Maintains Cronos Group(CRON.US) With Sell Rating, Cuts Target Price to $2Market Newswire · 2024/10/15
-
Rating change
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Cronos Group (CRON) and Boston Scientific (BSX)TipRanks · 2026/6/25
-
Rating change
CCORF Initiates Cronos Group(CRON.US) With Buy Rating, Announces Target Price $3.14Market Newswire · 2026/1/27
-
TD Cowen Maintains Cronos Group(CRON.US) With Buy Rating, Raises Target Price to $4.02Market Newswire · 2026/5/12
-
TD Cowen Maintains Cronos Group(CRON.US) With Buy Rating, Raises Target Price to $4.94Market Newswire · 2026/9/28
-
Cronos Group Announces Extension of Shr Repurchase Program to the Toronto Stk Exchange CRON.TDow Jones · 2026/6/17
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Cronos Group discussion 0 comments